Â鶹ӳ»­

Glioblastoma, the most common type of central nervous system tumor, is generally resistant to immune checkpoint blockade, highlighting a need to uncover potential features that can predict treatment response. In this Phase I/II trial, researchers led by Shiao-Pei Weathers, M.D., enrolled 60 patients with newly diagnosed glioblastoma to evaluate the safety and efficacy of combining the immune checkpoint inhibitor atezolizumab with the...